Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aligos, Alpine, Aqualung, Copernicus, G1, Gridiron, Inmune, Innovation1, Northeastern University, ST.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Corvia, Fluoguide, Kestra Medical Technologies, Natera.
A phase II/III trial testing Inflarx NV's vilobelimab, a monoclonal antibody the company is developing to control inflammatory response, showed a relative reduction in 28-day all-cause mortality of 23.9% vs. placebo (p=0.094) for mechanically ventilated COVID-19 patients, but missed statistical significance on the measure, the study's primary endpoint.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abionyx, Antengene, ASC, Biogen, Guerbet, Hipra, Nurix, Realta, Receptor, Taiho, Viiv.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Acer, Adagio, Ascletis, Cellphire, Concentric, Genentech, Immutep, Prometheus, Revelation.
RSS
